Madrigal Pharmaceuticals, Inc. (MDGL)
USD 314.54
(-3.84%)
USD 314.54
(-3.84%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 640.54 Million USD | 76.67% |
| 2022 | 362.57 Million USD | 32.65% |
| 2021 | 273.33 Million USD | -4.76% |
| 2020 | 286.99 Million USD | -35.08% |
| 2019 | 442.05 Million USD | -8.93% |
| 2018 | 485.42 Million USD | 152.42% |
| 2017 | 192.31 Million USD | 366.67% |
| 2016 | 41.21 Million USD | -39.57% |
| 2015 | 68.19 Million USD | -32.26% |
| 2014 | 100.67 Million USD | 5.75% |
| 2013 | 95.2 Million USD | -7.59% |
| 2012 | 103.01 Million USD | 143.4% |
| 2011 | 42.32 Million USD | -21.72% |
| 2010 | 54.06 Million USD | 10.54% |
| 2009 | 48.91 Million USD | -49.71% |
| 2008 | 97.25 Million USD | -20.71% |
| 2007 | 122.64 Million USD | 123.86% |
| 2006 | 54.78 Million USD | -23.06% |
| 2005 | 71.21 Million USD | -46.06% |
| 2004 | 132.01 Million USD | 64.23% |
| 2003 | 80.38 Million USD | 0.0% |
| 2001 | 2.77 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.08 Billion USD | 68.96% |
| 2024 Q3 | 1.07 Billion USD | -2.41% |
| 2024 Q2 | 1.09 Billion USD | 1.62% |
| 2023 Q2 | 302.46 Million USD | -9.02% |
| 2023 FY | 640.54 Million USD | 76.67% |
| 2023 Q1 | 332.44 Million USD | -8.31% |
| 2023 Q3 | 237.96 Million USD | -21.32% |
| 2023 Q4 | 640.54 Million USD | 169.18% |
| 2022 Q3 | 158.64 Million USD | -26.69% |
| 2022 Q4 | 362.57 Million USD | 128.54% |
| 2022 FY | 362.57 Million USD | 32.65% |
| 2022 Q2 | 216.39 Million USD | -2.82% |
| 2022 Q1 | 222.66 Million USD | -18.54% |
| 2021 Q2 | 327.95 Million USD | 5.88% |
| 2021 Q1 | 309.73 Million USD | 7.92% |
| 2021 Q3 | 304.69 Million USD | -7.09% |
| 2021 Q4 | 273.33 Million USD | -10.29% |
| 2021 FY | 273.33 Million USD | -4.76% |
| 2020 FY | 286.99 Million USD | -35.08% |
| 2020 Q4 | 286.99 Million USD | -15.49% |
| 2020 Q2 | 388.38 Million USD | -5.61% |
| 2020 Q1 | 411.45 Million USD | -6.92% |
| 2020 Q3 | 339.61 Million USD | -12.56% |
| 2019 FY | 442.05 Million USD | -8.93% |
| 2019 Q2 | 469.82 Million USD | -2.03% |
| 2019 Q3 | 456.25 Million USD | -2.89% |
| 2019 Q1 | 479.56 Million USD | -1.21% |
| 2019 Q4 | 442.05 Million USD | -3.11% |
| 2018 Q3 | 489.54 Million USD | -0.4% |
| 2018 Q1 | 183.47 Million USD | -4.59% |
| 2018 FY | 485.42 Million USD | 152.42% |
| 2018 Q2 | 491.52 Million USD | 167.89% |
| 2018 Q4 | 485.42 Million USD | -0.84% |
| 2017 Q4 | 192.31 Million USD | 206.08% |
| 2017 Q2 | 68.06 Million USD | 68.66% |
| 2017 Q1 | 40.35 Million USD | -2.07% |
| 2017 FY | 192.31 Million USD | 366.67% |
| 2017 Q3 | 62.83 Million USD | -7.69% |
| 2016 Q3 | 41.5 Million USD | -7.63% |
| 2016 FY | 41.21 Million USD | -39.57% |
| 2016 Q4 | 41.21 Million USD | -0.72% |
| 2016 Q1 | 52.97 Million USD | -22.33% |
| 2016 Q2 | 44.93 Million USD | -15.16% |
| 2015 Q3 | 91.01 Million USD | -10.37% |
| 2015 Q4 | 68.19 Million USD | -25.07% |
| 2015 FY | 68.19 Million USD | -32.26% |
| 2015 Q2 | 101.53 Million USD | 27.9% |
| 2015 Q1 | 79.39 Million USD | -21.14% |
| 2014 Q4 | 100.67 Million USD | -18.58% |
| 2014 Q1 | 82.18 Million USD | -13.67% |
| 2014 Q2 | 115.94 Million USD | 41.08% |
| 2014 Q3 | 123.65 Million USD | 6.65% |
| 2014 FY | 100.67 Million USD | 5.75% |
| 2013 Q1 | 93.7 Million USD | -9.04% |
| 2013 FY | 95.2 Million USD | -7.59% |
| 2013 Q4 | 95.2 Million USD | 68.02% |
| 2013 Q3 | 56.66 Million USD | -23.35% |
| 2013 Q2 | 73.92 Million USD | -21.11% |
| 2012 Q1 | 59.84 Million USD | 41.39% |
| 2012 Q3 | 57.61 Million USD | 22.15% |
| 2012 Q4 | 103.01 Million USD | 78.81% |
| 2012 FY | 103.01 Million USD | 143.4% |
| 2012 Q2 | 47.16 Million USD | -21.18% |
| 2011 Q3 | 53.86 Million USD | -17.91% |
| 2011 FY | 42.32 Million USD | -21.72% |
| 2011 Q4 | 42.32 Million USD | -21.43% |
| 2011 Q2 | 65.62 Million USD | 52.87% |
| 2011 Q1 | 42.92 Million USD | -20.61% |
| 2010 Q4 | 54.06 Million USD | -6.59% |
| 2010 Q3 | 57.88 Million USD | 10.14% |
| 2010 FY | 54.06 Million USD | 10.54% |
| 2010 Q2 | 52.55 Million USD | -15.98% |
| 2010 Q1 | 62.54 Million USD | 27.87% |
| 2009 Q1 | 91.75 Million USD | -5.65% |
| 2009 Q3 | 57.56 Million USD | -15.6% |
| 2009 Q4 | 48.91 Million USD | -15.03% |
| 2009 FY | 48.91 Million USD | -49.71% |
| 2009 Q2 | 68.2 Million USD | -25.67% |
| 2008 Q1 | 106.64 Million USD | -13.05% |
| 2008 Q4 | 97.25 Million USD | 7.15% |
| 2008 FY | 97.25 Million USD | -20.71% |
| 2008 Q3 | 90.76 Million USD | 4.25% |
| 2008 Q2 | 87.06 Million USD | -18.36% |
| 2007 FY | 122.64 Million USD | 123.86% |
| 2007 Q1 | 85.19 Million USD | 55.5% |
| 2007 Q2 | 71.6 Million USD | -15.96% |
| 2007 Q4 | 122.64 Million USD | 118.97% |
| 2007 Q3 | 56.01 Million USD | -21.77% |
| 2006 Q3 | 66.34 Million USD | 0.0% |
| 2006 Q4 | 54.78 Million USD | -17.42% |
| 2006 FY | 54.78 Million USD | -23.06% |
| 2005 Q4 | 71.21 Million USD | 0.0% |
| 2005 Q1 | 118.47 Million USD | 0.0% |
| 2005 FY | 71.21 Million USD | -46.06% |
| 2004 FY | 132.01 Million USD | 64.23% |
| 2003 FY | 80.38 Million USD | 0.0% |
| 2001 FY | 2.77 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 56.955% |
| Alkermes plc | 2.13 Billion USD | 70.015% |
| Agenus Inc. | 313.91 Million USD | -104.052% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 83.275% |
| Aptorum Group Limited | 20.64 Million USD | -3003.412% |
| Ardelyx, Inc. | 297.57 Million USD | -115.253% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 16.329% |
| Bicycle Therapeutics plc | 595.34 Million USD | -7.593% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -769.104% |
| ChromaDex Corporation | 54.96 Million USD | -1065.394% |
| Chimerix, Inc. | 212.77 Million USD | -201.046% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2165.627% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -45.259% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 71.27% |
| Precision BioSciences, Inc. | 159.78 Million USD | -300.891% |
| Dyadic International, Inc. | 8.21 Million USD | -7693.267% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1918.106% |
| Fortress Biotech, Inc. | 167.52 Million USD | -282.357% |
| Lantern Pharma Inc. | 43.64 Million USD | -1367.542% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -297.024% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -4315.541% |
| Incyte Corporation | 6.78 Billion USD | 90.555% |
| IO Biotech, Inc. | 150.71 Million USD | -324.997% |
| Jaguar Health, Inc. | 50.76 Million USD | -1161.838% |
| Novavax, Inc. | 1.85 Billion USD | 65.476% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -68.385% |
| Opthea Limited | 188.79 Million USD | -239.289% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 23.11% |
| ContextLogic Inc. | 423 Million USD | -51.43% |
| MiMedx Group, Inc. | 239.04 Million USD | -167.959% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -268.711% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -12290.407% |
| NextCure, Inc. | 129.41 Million USD | -394.944% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1087.342% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1643.982% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1883.056% |
| Vaxcyte, Inc. | 1.4 Billion USD | 54.504% |
| PDS Biotechnology Corporation | 59.39 Million USD | -978.542% |
| Pharming Group N.V. | 462.85 Million USD | -38.391% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1556.016% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -1.908% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3284.897% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3284.897% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -287.459% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1314.417% |
| Acelyrin, Inc. | 742.69 Million USD | 13.753% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -9625.116% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -9903.858% |
| Summit Therapeutics Inc. | 202.94 Million USD | -215.62% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -761.251% |
| Senti Biosciences, Inc. | 119.48 Million USD | -436.094% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -180.521% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -280.883% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -7651.991% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -13318.059% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -36.521% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -418.02% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -132.969% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -35.468% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -6238.911% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -198.615% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -56477.477% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -54.781% |
| Immix Biopharma, Inc. | 19.92 Million USD | -3114.765% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -73.109% |
| MEI Pharma, Inc. | 41.37 Million USD | -1448.15% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1876.631% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -87.955% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -446.425% |
| Fortress Biotech, Inc. | 167.52 Million USD | -282.357% |
| Precigen, Inc. | 151.04 Million USD | -324.083% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1782.965% |
| AlloVir, Inc. | 190.79 Million USD | -235.723% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -70.154% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -26.536% |
| ImmuCell Corporation | 43.8 Million USD | -1362.166% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 1.35% |
| Onconetix, Inc. | 88.82 Million USD | -621.163% |
| PureTech Health plc | 693.97 Million USD | 7.699% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -555.727% |
| Elevation Oncology, Inc. | 89.09 Million USD | -618.981% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -10228.072% |
| Seer, Inc. | 436.26 Million USD | -46.824% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -685.013% |
| Innoviva, Inc. | 1.24 Billion USD | 48.489% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -383.713% |
| ESSA Pharma Inc. | 149.12 Million USD | -329.545% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1313.497% |
| GT Biopharma, Inc. | 14.1 Million USD | -4439.989% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -108.042% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -165.014% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -35.736% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1163.481% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -572.759% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -101318.488% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -13.103% |
| Aptose Biosciences Inc. | 12.92 Million USD | -4856.818% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2796.531% |
| Soligenix, Inc. | 9.79 Million USD | -6437.978% |
| Century Therapeutics, Inc. | 360.69 Million USD | -77.589% |
| Kura Oncology, Inc. | 448.93 Million USD | -42.681% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -135.366% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -3603.654% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -477.531% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -212.232% |
| Autolus Therapeutics plc | 375.38 Million USD | -70.639% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -154.553% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -80.342% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1203.727% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 3.114% |
| GRI Bio, Inc. | 2.95 Million USD | -21569.384% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -5939.918% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -275.654% |
| IGM Biosciences, Inc. | 423.41 Million USD | -51.283% |
| INmune Bio, Inc. | 57 Million USD | -1023.747% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -187.879% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -663.09% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2352.619% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -9205.955% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -751.497% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -334.983% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -287.028% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -1.738% |
| Verastem, Inc. | 149.71 Million USD | -327.836% |
| Abeona Therapeutics Inc. | 64 Million USD | -900.823% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -25.069% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -314.709% |
| Histogen Inc. | 19.07 Million USD | -3258.397% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -2728.0% |
| Surrozen, Inc. | 46.08 Million USD | -1290.076% |
| Organovo Holdings, Inc. | 6.34 Million USD | -9988.943% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -14766.639% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -344.742% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -5327.445% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -751.022% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -7418.819% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -76.474% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -3440.03% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -49.172% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -4978.982% |
| Apollomics, Inc. | 55.38 Million USD | -1056.493% |
| Amarin Corporation plc | 831.68 Million USD | 22.982% |
| Mesoblast Limited | 669.15 Million USD | 4.275% |
| Turnstone Biologics Corp. | 112.81 Million USD | -467.785% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -11.253% |
| Synaptogenix, Inc. | 31.11 Million USD | -1958.732% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -5157.28% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -16.875% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -10808.013% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -8620.669% |
| Exelixis, Inc. | 2.94 Billion USD | 78.23% |
| Better Therapeutics, Inc. | 22.94 Million USD | -2691.906% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -75.714% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 18.788% |
| NLS Pharmaceutics AG | 1.84 Million USD | -34587.143% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -7928.279% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -4258.945% |
| Gritstone bio, Inc. | 177.76 Million USD | -260.325% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -571.574% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -3486.034% |
| Avid Bioservices, Inc. | 336.55 Million USD | -90.323% |
| Insmed Incorporated | 1.32 Billion USD | 51.833% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -6552.722% |
| MediWound Ltd. | 66.45 Million USD | -863.823% |
| OmniAb, Inc. | 401.98 Million USD | -59.346% |
| Alector, Inc. | 621.82 Million USD | -3.01% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -78.624% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -11810.506% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1029.872% |
| Zai Lab Limited | 1.03 Billion USD | 38.189% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -33.878% |
| Aura Biosciences, Inc. | 255.07 Million USD | -151.121% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 14.597% |
| Immunic, Inc. | 54.29 Million USD | -1079.666% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -140.605% |
| Veracyte, Inc. | 1.13 Billion USD | 43.704% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -5317.904% |
| FibroGen, Inc. | 423.52 Million USD | -51.24% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -18133.618% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -13423.336% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -11697.58% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 94.378% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -7174.81% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -23.788% |
| TG Therapeutics, Inc. | 329.58 Million USD | -94.348% |
| Galecto, Inc. | 38.22 Million USD | -1575.64% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2133.739% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 85.299% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -172.105% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -2478.484% |
| XBiotech Inc. | 227.24 Million USD | -181.878% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -571.574% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -349.191% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -124.033% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -400.94% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -67.683% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 57.039% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -75.568% |
| Vaxxinity, Inc. | 44.35 Million USD | -1344.202% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -23.906% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -3342.074% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -109.981% |
| NexImmune, Inc. | 8.59 Million USD | -7353.465% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -5877.934% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -3639.898% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.064% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2791.712% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -163194.457% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -269.556% |
| Ainos, Inc. | 31.84 Million USD | -1911.654% |
| Pluri Inc. | 39.52 Million USD | -1520.53% |
| Prothena Corporation plc | 696.38 Million USD | 8.018% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -126.649% |
| Celularity Inc. | 143.88 Million USD | -345.167% |
| Rallybio Corporation | 115.62 Million USD | -454.011% |
| Cue Biopharma, Inc. | 61.53 Million USD | -941.032% |
| MeiraGTx Holdings plc | 458.16 Million USD | -39.806% |
| Omeros Corporation | 378.26 Million USD | -69.336% |
| Humacyte, Inc. | 128.22 Million USD | -399.557% |
| Immunocore Holdings plc | 597 Million USD | -7.294% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1949.16% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -834.696% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 38.952% |
| CalciMedica, Inc. | 12.18 Million USD | -5156.849% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -152.532% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -274.791% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -105.94% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -13.311% |
| Pulmatrix, Inc. | 33.95 Million USD | -1786.292% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2259.637% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -354.747% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 50.764% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -392.013% |
| Cytokinetics, Incorporated | 824.31 Million USD | 22.294% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2932.462% |
| Nutriband Inc. | 7.51 Million USD | -8421.137% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -711.291% |
| Vor Biopharma Inc. | 209.82 Million USD | -205.272% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 91.131% |
| Evogene Ltd. | 51.1 Million USD | -1153.492% |
| ProKidney Corp. | 420.55 Million USD | -52.311% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1068.178% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -6628.238% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -17.235% |
| CorMedix Inc. | 82.05 Million USD | -680.584% |
| BioLineRx Ltd. | 63.92 Million USD | -902.029% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -59.116% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2171.443% |
| Atai Life Sciences N.V. | 293.47 Million USD | -118.261% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -292.662% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -402.713% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -13.971% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -562.276% |
| MediciNova, Inc. | 66.26 Million USD | -866.572% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -628.325% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -14254.429% |
| GeoVax Labs, Inc. | 9.28 Million USD | -6800.053% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -8.893% |
| Biomea Fusion, Inc. | 199.92 Million USD | -220.39% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 66.343% |
| Mereo BioPharma Group plc | 66.49 Million USD | -863.243% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -32.045% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -4.514% |
| Absci Corporation | 234.48 Million USD | -173.178% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -8656.623% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -88.457% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -288.017% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -21.702% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -130.667% |
| Allakos Inc. | 243.61 Million USD | -162.94% |
| Imunon, Inc. | 21.91 Million USD | -2822.461% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -148.569% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -3.062% |
| BioAtla, Inc. | 119.65 Million USD | -435.315% |
| NLS Pharmaceutics AG | 1.84 Million USD | -34587.143% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -19792.764% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 0.356% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -567.689% |
| XOMA Corporation | 234.3 Million USD | -173.386% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -189.532% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -409.001% |
| aTyr Pharma, Inc. | 122.06 Million USD | -424.75% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -316.202% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -10.388% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -30.611% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -479.843% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -4125.925% |
| Akari Therapeutics, Plc | 4.35 Million USD | -14608.312% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3659.667% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 63.044% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -20670.101% |
| UroGen Pharma Ltd. | 178.31 Million USD | -259.23% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -36.074% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -115165.379% |
| Orgenesis Inc. | 14.55 Million USD | -4301.78% |
| Entera Bio Ltd. | 11.76 Million USD | -5344.513% |
| GH Research PLC | 226.3 Million USD | -183.052% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1071.147% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -496.213% |
| Xencor, Inc. | 952.69 Million USD | 32.765% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -8129.263% |
| Replimune Group, Inc. | 487.72 Million USD | -31.334% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -7836.314% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 1.217% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -20670.101% |
| Portage Biotech Inc. | 7.77 Million USD | -8134.31% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -14254.429% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -131.29% |
| OncoCyte Corporation | 74.89 Million USD | -755.294% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -31403.634% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -10969.406% |
| Purple Biotech Ltd. | 44.3 Million USD | -1345.865% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1777.006% |
| scPharmaceuticals Inc. | 94.47 Million USD | -577.978% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -3449.728% |
| HilleVax, Inc. | 344.43 Million USD | -85.971% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -20068.356% |
| Tharimmune, Inc. | 10.94 Million USD | -5751.672% |
| Genprex, Inc. | 10.67 Million USD | -5902.919% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -29.092% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -565.49% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -26303.421% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -15277.651% |
| OKYO Pharma Limited | 1.54 Million USD | -41459.85% |
| Savara Inc. | 177.56 Million USD | -260.741% |
| Curis, Inc. | 77.28 Million USD | -728.844% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2909.776% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -901.656% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -7821.679% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -3206.732% |
| BeiGene, Ltd. | 5.8 Billion USD | 88.966% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -5163.76% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 69.331% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -78.948% |
| Erasca, Inc. | 395.29 Million USD | -62.042% |
| bluebird bio, Inc. | 619.16 Million USD | -3.454% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -14715.922% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 90.637% |
| DBV Technologies S.A. | 182.98 Million USD | -250.052% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -14715.922% |
| Moderna, Inc. | 18.42 Billion USD | 96.524% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -3416.205% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -5428.629% |
| Molecular Templates, Inc. | 35.38 Million USD | -1710.324% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -363.275% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 18.806% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -110.876% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -516.231% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -37.567% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -104.362% |
| MacroGenics, Inc. | 306.82 Million USD | -108.77% |
| RenovoRx, Inc. | 1.46 Million USD | -43593.52% |
| Adicet Bio, Inc. | 207.29 Million USD | -209.003% |
| Prime Medicine, Inc. | 193.85 Million USD | -230.433% |
| Aditxt, Inc. | 44.57 Million USD | -1336.902% |
| Adagene Inc. | 115.72 Million USD | -453.49% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -14280.777% |
| Quantum-Si incorporated | 298.25 Million USD | -114.768% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 56.937% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -8208.948% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -82.346% |
| SciSparc Ltd. | 11.18 Million USD | -5628.376% |
| Vericel Corporation | 353.65 Million USD | -81.121% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -5144.964% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1025.73% |
| Generation Bio Co. | 374.75 Million USD | -70.923% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -151.524% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -303.96% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -87.643% |
| Invivyd, Inc. | 229.18 Million USD | -179.494% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 24.104% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -5163.63% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -251.196% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3036.247% |
| 2seventy bio, Inc. | 565.42 Million USD | -13.286% |
| ADMA Biologics, Inc. | 329.18 Million USD | -94.587% |
| Clene Inc. | 52.34 Million USD | -1123.796% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -990.584% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -393.131% |
| GeoVax Labs, Inc. | 9.28 Million USD | -6800.053% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 2.012% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -518.222% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -391.27% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -556.621% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -802.217% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -164.085% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 67.321% |
| Evaxion Biotech A/S | 12.88 Million USD | -4869.865% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -154.125% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 14.899% |
| Trevena, Inc. | 40.6 Million USD | -1477.508% |
| Surrozen, Inc. | 46.08 Million USD | -1290.076% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -183.607% |
| Cingulate Inc. | 3.49 Million USD | -18246.233% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -3751.987% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -875.106% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -5381.964% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -138.55% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 14.475% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -408.807% |
| Clearmind Medicine Inc. | 4.32 Million USD | -14712.428% |
| Kronos Bio, Inc. | 213.27 Million USD | -200.333% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -300.883% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -7382.492% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -73.83% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2925.775% |
| ImmunityBio, Inc. | 504.45 Million USD | -26.979% |
| Korro Bio, Inc. | 221.66 Million USD | -188.973% |
| Kineta, Inc. | 10.28 Million USD | -6130.396% |
| BioVie Inc. | 25.2 Million USD | -2441.012% |
| Codexis, Inc. | 136.56 Million USD | -369.056% |
| Celularity Inc. | 143.88 Million USD | -345.167% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -0.817% |
| Celcuity Inc. | 191.21 Million USD | -234.98% |
| Virax Biolabs Group Limited | 5.48 Million USD | -11580.354% |
| Cibus, Inc. | 544.41 Million USD | -17.659% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -408.799% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3017.927% |
| IN8bio, Inc. | 33.7 Million USD | -1800.225% |
| Kodiak Sciences Inc. | 479.37 Million USD | -33.622% |
| Annexon, Inc. | 297.67 Million USD | -115.184% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -270.237% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -365.957% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2951.241% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 78.578% |
| Eyenovia, Inc. | 28.77 Million USD | -2125.716% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -177.861% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -8766.93% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -951.352% |
| Arcellx, Inc. | 825.13 Million USD | 22.37% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -684.628% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -38.564% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1983.08% |
| Moolec Science SA | 24.05 Million USD | -2563.254% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -106.545% |
| Geron Corporation | 394.07 Million USD | -62.544% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -529.778% |
| Royalty Pharma plc | 16.38 Billion USD | 96.09% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -7.661% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -9057.454% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -5225.768% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -183.353% |
| Humacyte, Inc. | 128.22 Million USD | -399.557% |
| Structure Therapeutics Inc. | 482.01 Million USD | -32.889% |
| 89bio, Inc. | 596.26 Million USD | -7.426% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -154.032% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -34524.162% |
| Genelux Corporation | 27.89 Million USD | -2196.444% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -616.471% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -179.192% |
| Notable Labs, Ltd. | 19.54 Million USD | -3177.964% |
| Liquidia Corporation | 120.43 Million USD | -431.879% |
| Mustang Bio, Inc. | 17.74 Million USD | -3510.343% |
| Immunovant, Inc. | 666.71 Million USD | 3.924% |
| Quantum-Si incorporated | 298.25 Million USD | -114.768% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -343.589% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1082.694% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -264.888% |
| Acasti Pharma Inc. | 73.3 Million USD | -773.87% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -13970.902% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2352.619% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 33.608% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -12242.141% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -2711.76% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1141.298% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -254.499% |
| PepGen Inc. | 143.05 Million USD | -347.772% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1576.079% |
| United Therapeutics Corporation | 7.16 Billion USD | 91.063% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -3238.791% |
| Solid Biosciences Inc. | 164.93 Million USD | -288.354% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -10808.013% |
| Immuneering Corporation | 102.58 Million USD | -524.409% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -14766.639% |
| Silo Pharma, Inc. | 7.74 Million USD | -8169.24% |
| Belite Bio, Inc | 94.64 Million USD | -576.811% |
| XOMA Corporation | 234.3 Million USD | -173.386% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -174.691% |
| Bionomics Limited | 27.64 Million USD | -2216.702% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -59.577% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -496.479% |
| uniQure N.V. | 831.68 Million USD | 22.982% |
| Cassava Sciences, Inc. | 151.66 Million USD | -322.349% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -14280.777% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -133.874% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1543.271% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -15626.223% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1639.152% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -8766.93% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -18133.618% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -5318.721% |
| Altimmune, Inc. | 210.64 Million USD | -204.096% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 17.655% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -496.479% |
| Compugen Ltd. | 121.33 Million USD | -427.92% |
| Peak Bio, Inc. | 2.59 Million USD | -24570.44% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -271.704% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1126.867% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -87.372% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1742.082% |
| Zura Bio Limited | 100.84 Million USD | -535.192% |
| PolyPid Ltd. | 15.37 Million USD | -4066.972% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -436.984% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1742.082% |
| Instil Bio, Inc. | 325.63 Million USD | -96.71% |
| argenx SE | 4.54 Billion USD | 85.899% |
| Immunome, Inc. | 148.54 Million USD | -331.229% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -308.317% |
| Verona Pharma plc | 308.12 Million USD | -107.886% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -636.608% |
| Shattuck Labs, Inc. | 159.56 Million USD | -301.436% |
| CervoMed Inc. | 9.97 Million USD | -6323.12% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -239.892% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -5524.754% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -257.04% |
| Moolec Science SA | 24.05 Million USD | -2563.254% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -10370.766% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -270.377% |
| AnaptysBio, Inc. | 452.38 Million USD | -41.592% |
| Design Therapeutics, Inc. | 289.64 Million USD | -121.151% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -779.57% |
| NeurAxis, Inc. | 509.49 Thousand USD | -125621.2% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -11722.573% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1476.227% |
| Achilles Therapeutics plc | 161.45 Million USD | -296.732% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -636.608% |
| 180 Life Sciences Corp. | 5.25 Million USD | -12078.913% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -809.509% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -7382.492% |
| Nutriband Inc. | 7.51 Million USD | -8421.137% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -151.505% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -221.397% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -740.481% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1005.993% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -21.652% |
| Palisade Bio, Inc. | 14.05 Million USD | -4458.404% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -204.594% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 56.118% |
| Neurogene Inc. | 222.57 Million USD | -187.792% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 0.939% |
| AEON Biopharma, Inc. | 6.84 Million USD | -9257.882% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -41.39% |
| Sesen Bio, Inc. | 189.17 Million USD | -238.602% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -135.61% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -4571.478% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 17.916% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -139.911% |
| Athira Pharma, Inc. | 160.24 Million USD | -299.73% |
| Vaccinex, Inc. | 3.63 Million USD | -17541.063% |
| HCW Biologics Inc. | 28.51 Million USD | -2146.457% |
| XOMA Corporation | 234.3 Million USD | -173.386% |
| Nektar Therapeutics | 398.03 Million USD | -60.928% |
| Arvinas, Inc. | 1.3 Billion USD | 50.901% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3659.667% |
| Merus N.V. | 458.49 Million USD | -39.707% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -213.431% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -255.457% |
| Rezolute, Inc. | 132.73 Million USD | -382.569% |
| Clene Inc. | 52.34 Million USD | -1123.796% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -4192.095% |
| BeyondSpring Inc. | 24.8 Million USD | -2482.018% |
| Synlogic, Inc. | 75.55 Million USD | -747.845% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -5299.992% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -6740.528% |
| Peak Bio, Inc. | 2.59 Million USD | -24570.44% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -266.376% |
| Krystal Biotech, Inc. | 818.35 Million USD | 21.727% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -166.408% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 11.745% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -17806.509% |
| MannKind Corporation | 475.19 Million USD | -34.796% |
| Ikena Oncology, Inc. | 192.09 Million USD | -233.458% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -4689.495% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -449.642% |
| Gossamer Bio, Inc. | 311.91 Million USD | -105.359% |
| CohBar, Inc. | 16.36 Million USD | -3813.968% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1721.651% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -8656.623% |
| Legend Biotech Corporation | 1.84 Billion USD | 65.35% |
| Mural Oncology plc | 301.74 Million USD | -112.281% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1952.049% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -11176.432% |
| Disc Medicine, Inc. | 367.99 Million USD | -74.064% |
| Champions Oncology, Inc. | 26.13 Million USD | -2351.198% |
| REGENXBIO Inc. | 573.97 Million USD | -11.599% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -23553.135% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -314.9% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -5204.482% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -88.377% |
| Vaxart, Inc. | 91.83 Million USD | -597.536% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -969.291% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -331.848% |
| Cellectis S.A. | 334.27 Million USD | -91.626% |
| Longeveron Inc. | 12.17 Million USD | -5159.87% |
| Repare Therapeutics Inc. | 253.9 Million USD | -152.282% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 80.379% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -218.923% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 69.331% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -39318.277% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -130.652% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -292.737% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -361.675% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2409.784% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.182% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 44.489% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -5144.964% |
| Veru Inc. | 50.59 Million USD | -1166.005% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1306.158% |
| Cingulate Inc. | 3.49 Million USD | -18246.233% |
| Passage Bio, Inc. | 150.54 Million USD | -325.485% |
| Context Therapeutics Inc. | 16.06 Million USD | -3887.783% |
| Exicure, Inc. | 11.58 Million USD | -5431.494% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -70.336% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -296.275% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -3566.134% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -92.504% |
| Nuvalent, Inc. | 732.38 Million USD | 12.539% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -4186.293% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -615.263% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -4413.755% |
| OmniAb, Inc. | 401.98 Million USD | -59.346% |
| Anew Medical, Inc. | 19.45 Million USD | -3192.293% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2296.669% |
| Lipocine Inc. | 23 Million USD | -2684.857% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -358.165% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -109.627% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -663.09% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -427.026% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -7972.426% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 27.398% |
| Ocugen, Inc. | 64.54 Million USD | -892.373% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -414.326% |
| Q32 Bio Inc. | 306.11 Million USD | -109.248% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -15122.125% |
| Alumis Inc. Common Stock | 89.61 Million USD | -614.8% |
| Equillium, Inc. | 50.53 Million USD | -1167.657% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -751.848% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1451.956% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -37560.339% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -2350.354% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -894.005% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -17086.144% |
| Dominari Holdings Inc. | 57.55 Million USD | -1012.872% |
| Edesa Biotech, Inc. | 8.89 Million USD | -7104.899% |
| vTv Therapeutics Inc. | 11.01 Million USD | -5713.641% |
| Bio-Techne Corporation | 2.81 Billion USD | 77.231% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 31.647% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 21.061% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -130.691% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1436.01% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 4.051% |
| Nkarta, Inc. | 378.88 Million USD | -69.061% |
| BioCardia, Inc. | 2.98 Million USD | -21344.493% |
| Iterum Therapeutics plc | 26.25 Million USD | -2339.343% |